Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA

被引：0
|
作者：
Barnett, Reagan
Lanka, Sree M.
Clemens, Keelia M.
Kiedrowski, Lesli Ann
Babiker, Hani M.
Bryce, Alan Haruo
Meyer, Haley M.
Choi, Yujin
Garje, Rohan
Gao, Xin
Chang, Richard Y.
Jang, Albert
Gulhati, Pat
Bilen, Mehmet Asim
Barata, Pedro C.
机构：
[1] Guardant Hlth Inc, Redwood City, CA USA
[2] Tulane Univ, New Orleans, LA USA
[3] Mayo Clin Florida, Jacksonville, FL USA
[4] Mayo Clin, Phoenix, AZ USA
[5] Mayo Clin, Scottsdale, AZ USA
[6] Emory Univ, Atlanta, GA USA
[7] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[8] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[9] Harvard Med Sch, Boston, MA USA
[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[11] Tulane Univ, Sch Med, New Orleans, LA USA
[12] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2561
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Impact of circulating tumor DNA (ctDNA) detection on survival outcomes of patients (pts) treated with immune-checkpoint inhibitors (ICIs) in early clinical trials.
    Galvao, Vladimir
    Matos, Ignacio
    Moreno, Ana
    Alonso, Guzman
    Brana, Irene
    Villar, Maria
    Gadea, Omar Saavedra Santa
    Oberoi, Honey Kumar
    Ros, Javier
    Berche, Roger
    Ann Wornham, Natassia
    Arenillas, Carlota
    Saura, Cristina
    Oaknin, Ana
    Felip, Enriqueta
    Munoz-Couselo, Eva
    Elez, Elena
    Tabernero, Josep
    Toledo, Rodrigo
    Garralda, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Clinical outcomes patients with high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency in a multi-institutional endometrial cancer consortium
    Lee, Sarah
    Secord, Angeles Alvarez
    Hade, Erinn
    Smitherman, Carson
    Bisht, Nikita
    Borden, Lindsay
    Jackson, Amanda
    Backes, Floor
    Thaker, Premal
    Arend, Rebecca
    Wright, Jason
    Corr, Bradley
    Ko, Emily
    Konecny, Gottfried
    Podwika, Sarah
    Bae-Jump, Victoria
    Pothuri, Bhavana
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S22 - S22
  • [33] Tumor mutational burden (TMB) and genomic predictors of clinical outcomes to PD-1/PD-L1 checkpoint blockade in high-grade gliomas
    Iorgulescu, Bryan
    Touat, Mehdi
    Li, Yvonne
    Spurr, Liam
    Grant, Gareth
    Pisano, William
    Lim-Fat, Mary Jane
    Lee, Eudocia
    Nayak, Lakshmi
    Chiocca, E.
    Huang, Raymond
    Cherniack, Andrew
    Wen, Patrick
    Idbaih, Ahmed
    Bielle, Franck
    Reardon, David
    Ligon, Keith
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [34] Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden
    Wang, Rong
    Yang, Yuchen
    Ye, Wei-Wu
    Xiang, Jianxing
    Chen, Songan
    Zou, Wei-Bin
    Wang, Xiao-Jia
    Chen, Tianhui
    Cao, Wen-Ming
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [35] Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness
    Mahipal, Amit
    Quintanilha, Julia C. F.
    Graf, Ryon
    Storandt, Michael H.
    Keller, Rachel B.
    Li, Gerald
    Ross, Jeffrey S.
    Huang, Richard S. P.
    Schrock, Alexa Betzig
    Oxnard, Geoffrey R.
    Chakrabarti, Sakti
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers A Systematic Review and Meta-analysis
    Petrelli, Fausto
    Ghidini, Michele
    Ghidini, Antonio
    Tomasello, Gianluca
    JAMA ONCOLOGY, 2020, 6 (07) : 1068 - 1071
  • [37] De-risking 1st line chemotherapy-free immune checkpoint inhibitor (ICI) use for patients with advanced gastroesophageal cancer (aGEJ) with tumor mutational burden (TMB).
    Klempner, Samuel J.
    Quintanilha, Julia
    Aboosaiedi, Ali
    Morley, Samantha
    Mitchell, Jerry W.
    Ross, Jeffrey S.
    Graf, Ryon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 407 - 407
  • [38] The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment
    Sakata, Yoshihiko
    Kawamura, Kodai
    Ichikado, Kazuya
    Shingu, Naoki
    Yasuda, Yuko
    Eguchi, Yoshitomo
    Anan, Keisuke
    Hisanaga, Junpei
    Nitawaki, Tatsuya
    Iio, Miwa
    Sekido, Yuko
    Nakan, Aiko
    Sakagami, Takuro
    LUNG CANCER, 2019, 130 : 159 - 161
  • [39] The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer
    Zhao, Jing
    Wu, Yang
    Yue, Yuan
    Chen, Minjiang
    Xu, Yan
    Liu, Xiangning
    Liu, Xiaoyan
    Gao, Xiaoxing
    Wang, Hanping
    Si, Xiaoyan
    Zhong, Wei
    Zhang, Xiaotong
    Zhang, Li
    Wang, Mengzhao
    THORACIC CANCER, 2023, 14 (05) : 497 - 505
  • [40] A Modi fied Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Rede fine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Bene fits From Immune Checkpoint Inhibitor Therapy
    Liu, Zhichao
    Xie, Zhanhong
    Cai, Xiuyu
    He, Jianxing
    Liang, Wenhua
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) : E69 - E72
12345